Irinotecan and Capecitabine in Treating Patients With Solid Tumors

Phase 1 Completed 30 enrolled Montefiore Medical Center National Cancer Institute (NCI) · collab

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan and capecitabine in treating patients who have solid tumors that have not responded to previous treatment.

Timeline

Start: 1999-03
Primary completion: 2003-03
Completion: 2003-03

Publications

Results Goel S, Jhawer M, Rajdev L, Hopkins U, Fehn K, Baker C, Chun HG, Makower D, Landau L, Hoffman A, Wadler S, Mani S. Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies. Am J Clin Oncol. 2002 Oct;25(5):528-34. doi: 10.1097/00000421-200210000-00022.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Capecitabine	Small molecule	1500 mg	Oral
Subject	Capecitabine	Small molecule	2300 mg	Oral
Subject	Capecitabine	Small molecule	3000 mg	Oral
Subject	Irinotecan	Small molecule	200 mg/m2	Intravenous
Subject	Irinotecan	Small molecule	275 mg/m2	Intravenous
Subject	Irinotecan	Small molecule	300 mg/m2	Intravenous

Irinotecan and Capecitabine in Treating Patients With Solid Tumors

Summary

Timeline

Publications

Drugs

Indications